Gen-Probe (GPRO) Tops Q3 EPS by 6c; Narrows Guidance
More News related to GPRO
- Trading Review for Cerus Corp. Issued by Beacon Equity
- Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
- Natixis Bleichroeder Initiates Coverage on Gen-Probe (GPRO) with a Buy
- Xenomics, Inc. and Its Subsidiary TrovaGene, Inc. Announce HPV Patent Filing Based on Transrenal DNA Technology
- Gen-Probe to Webcast Two Upcoming Investor Presentations
Gen-Probe (NASDAQ: GPRO) reports Q3 EPS of $0.47, cents better than the analyst estimate of $0.41. Revenue for the quarter was $ million, which compares to the estimate of $123.31 million.
Gen-Probe narrows FY EPS from $1.85-$1.95, to $1.90-$1.93 and the consensus of $1.88. Gen-Probe sees sales of $490-$503 versus prior view of $493-$500 million and the consensus of $493 million.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.29Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
